Physician profile
Richard Griffiths
NPI 1881646180
$925,004.43
in general payments reported to CMS, 2019-2025
25 companies · $158K in 2025
The $158K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $82K · 2021: $92K · 2022: $225K · 2023: $198K · 2024: $153K · 2025: $158K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $509K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $508,658.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $346,292.30 | 2022-2025 | |
| Csl Behring | $311,437.50 | 2019-2022 | |
| Csl Plasma INC. | $263,500.70 | 2023-2025 | |
| Novo Nordisk INC | $1,372.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $366.29 | 2019-2020 | |
| Amgen INC. | $335.09 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $252.70 | 2019-2020 | |
| Abbott Laboratories | $241.12 | 2019-2020 | |
| Insulet Corporation | $222.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $195.51 | 2019-2020 | |
| Corcept Therapeutics | $185.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $140.37 | 2019 | |
| Dexcom, INC. | $73.41 | 2019-2020 | |
| Valeritas, INC. | $72.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $62.23 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.47 | 2019-2020 | |
| Medtronic Minimed, INC. | $41.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.16 | 2019 | |
| Pfizer INC. | $25.59 | 2019 | |
| Amarin Pharma, INC. | $20.26 | 2019 | |
| Abbvie INC. | $18.72 | 2019 | |
| Shire North American Group INC | $18.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Lifescan, INC. | $11.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Griffiths listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.